Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial

Invernizzi, Pietro; Carbone, Marco; Jones, David; Levy, Cynthia; Little, Nicola; Wiesel, Philippe; Nevens, Frederik; study investigators, the

doi:10.1111/liv.15596

Public

Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial

Published in Liver International • May 15, 2023

Authors:

Pietro Invernizzi

Marco Carbone

David Jones

Abstract

BACKGROUND: Primary biliary cholangitis (PBC) is a rare liver disease with significant unmet need for second-line/add-on treatments. Setanaxib, a NOX1/4 inhibitor, has shown anti-fibrotic effects in in vitro and animal studies. This phase 2, randomized, multicentre study investigated the efficacy an...

Subject

Placebo

Medicine

Ursodeoxycholic acid

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!